SAGES 呼吁同步管理重度肥胖与结直肠癌
SAGES 结直肠与代谢减重手术委员会联合工作组指出,重度肥胖与结直肠癌围手术期并发症增加及肿瘤学结局不良独立相关,但术前减重未常规纳入管理。文献综述结合三例新辅助治疗期间同步减重案例,提示代谢优化可行但缺乏前瞻性证据。
要点
- 重度肥胖增加结直肠癌分期困难、吻合口漏、手术部位感染及中转开腹风险。
- 当前结直肠癌指南未纳入结构化减重策略,需多学科协作探索代谢优化。
- 减重手术或药物在新辅助窗口期减重可行,但缺乏前瞻性结局数据。
核心结论
- 重度肥胖对结直肠癌分期、手术复杂性和围手术期结局产生不利影响。
- 通过减重手术或药物治疗进行有意的代谢优化,可能成为多学科以患者为中心的结直肠癌诊疗路径中的可行辅助手段。
- 缺乏前瞻性短期和长期结局数据,需要系统研究以确定减重干预的最佳时机、安全参数和肿瘤学疗效。
研究设计与样本
- 文献综述:检索 PubMed 和 Embase,纳入同行评议的英文成人研究,排除会议摘要、非英文文献及与肥胖和结直肠癌无关的研究。
- 在缺乏已发表的重度肥胖患者同步减重与结直肠癌管理报告的情况下,纳入三例新的回顾性病例(经机构审查委员会批准)以展示新辅助治疗期间的可行性。
主要发现
- 重度肥胖因横断面成像和解剖 delineation 的限制而使结直肠癌分期复杂化。
- 重度肥胖,尤其是内脏肥胖,与吻合口漏、手术部位感染和转为开腹手术的发生率增加相关。
- 袖状胃切除术等代谢减重手术可实现快速且有临床意义的体重减轻,常改善后续切除术的手术暴露和技术条件。
- 药物治疗更易获得且侵入性更小,但通常对内脏脂肪的减少幅度更有限。
- 三例局部晚期结直肠癌伴重度肥胖患者在新辅助窗口期通过多学科协调(包括代谢减重手术或药物治疗)成功实现术前内脏脂肪减少,随后进行根治性肿瘤切除。
临床怎么用
- 对重度肥胖的结直肠癌患者,在多学科诊疗中考虑评估同步代谢优化的可行性。
- 新辅助治疗窗口期可个体化选择减重手术或药物治疗以减少内脏脂肪、改善手术条件。
- 当前证据不足以支持常规推荐,需在临床研究框架下审慎实施并系统收集结局。
局限性
- 缺乏前瞻性短期和长期结局数据。
- 仅有文献综述和三例回顾性病例经验,证据等级有限。
- 减重干预的最佳时机、安全参数和肿瘤学疗效尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe obesity (body mass index ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity-related comorbidities) is increasingly prevalent and independently associated with elevated perioperative morbidity and inferior oncologic outcomes in patients with colorectal cancer (CRC). Despite these risks, intentional preoperative weight optimization is not routinely incorporated into CRC management, owing to concerns regarding treatment delay, absence of guideline endorsement, and limited supporting evidence. METHODS: A literature review was conducted using PubMed and Embase to evaluate the impact of severe obesity on morbidity, mortality, and oncologic outcomes in CRC. Peer-reviewed English-language studies involving adult human subjects were included, while conference abstracts, non-English publications, and studies unrelated to obesity and CRC were excluded. In the absence of published reports describing synchronized weight loss and CRC management in patients with severe obesity, three novel retrospective case examples were included to demonstrate feasibility during neoadjuvant treatment, with institutional review board approval obtained for all cases. RESULTS: Severe obesity complicates CRC staging due to limitations in cross-sectional imaging and anatomic delineation. Furthermore, severe and particularly visceral obesity is associated with increased rates of anastomotic leak, surgical site infection, and conversion to open surgery. Current CRC guidelines do not incorporate structured weight-loss strategies into standard treatment algorithms. Metabolic bariatric procedures, such as sleeve gastrectomy, achieve rapid and clinically meaningful weight reduction, often resulting in improved operative exposure and technical conditions for subsequent resection. Pharmacologic therapies, while more broadly accessible and less invasive, typically yield more modest reductions in visceral adiposity. Task force members report early experience across three distinct cases of locally advanced CRC in patients with severe obesity, demonstrating successful preoperative visceral fat reduction through multidisciplinary coordination incorporating metabolic bariatric surgery or pharmacologic therapy during neoadjuvant windows, followed by definitive oncologic resection. CONCLUSIONS: Severe obesity adversely influences CRC staging, operative complexity, and perioperative outcomes. Intentional metabolic optimization-through bariatric surgery or pharmacologic therapy-may represent a viable adjunct within multidisciplinary, patient-centered CRC care pathways. However, the absence of prospective short- and long-term outcome data underscores the need for systematic investigation to define optimal timing, safety parameters, and oncologic efficacy of weight-loss interventions in this high-risk population.
引用
- Kaiser AM, Carmichael H, Lee L, et al. SAGES colorectal and metabolic bariatric surgery committee joint task force call to action for synchronized severe obesity and colorectal cancer management. Surg Endosc. 2026. PMID: 42151463. doi:10.1007/s00464-026-12878-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。